系统性硬化症患者感染COVID-19的影响是否随时间变化?
该研究纳入2020年4月至2021年4月EUSTAR登记的333例系统性硬化症合并COVID-19患者,按诊断时间分为第1、2、3波。结果显示第2、3波较第1波严重结局、住院、通气支持和死亡均显著减少(P<0.001、P=0.001、P=0.011)。
要点
- 共333例SSc合并COVID-19患者,57例(17%)发生严重结局,30例(9%)死亡。
- 第2、3波较第1波严重COVID-19比例显著降低(28.2% vs 9.8%和12.7%,P<0.001)。
- 第2、3波较第1波住院、通气支持和死亡均显著减少。
核心结论
- 系统性硬化症合并COVID-19患者的结局随时间显著改善,归因于内在和外在因素。
研究设计与样本
- 研究收集2020年4月至2021年4月EUSTAR登记的系统性硬化症合并COVID-19患者,按COVID-19诊断日期分为第1、2、3波,采用描述性统计和多变量逻辑回归分析。
主要发现
- 共纳入333例患者,57例(17%)发生严重结局,30例(9%)死亡。
- 与第1波相比,第2、3波严重COVID-19比例显著降低(28.2% vs 9.8%和12.7%,P<0.001)。
- 与第1波相比,第2、3波住院比例显著降低(46.7% vs 19.6%和25.5%,P<0.001)。
- 与第1波相比,第2、3波通气支持比例显著降低(24.0% vs 8.7%和10.9%,P=0.001)。
- 与第1波相比,第2、3波死亡比例显著降低(15.7% vs 5.0%和7.5%,P=0.011)。
关键数值与推荐
- 严重结局定义为死亡、重症监护室住院或通气支持。
- 随时间推移(第1至3波),患者显著更年轻、男性更多、动脉性高血压更少、SSc心脏受累更少。
- 随时间推移,患者接受的SSc治疗中中至高剂量糖皮质激素显著更少。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The outcome of patients with COVID-19 improved over the pandemic, including patients with systemic rheumatic diseases. However, data on patients with systemic sclerosis (SSc) are lacking. This study aimed to assess the outcome of patients with both SSc and COVID-19 over several waves. METHODS: Patients with both SSc and COVID-19 who were registered in the European Scleroderma Trials and Research group (EUSTAR) were collected between April 2020 and April 2021. Patients were assigned to waves 1, 2, or 3 depending on the date of their COVID-19 diagnosis. Primary endpoints were death, intensive care unit stay, or ventilatory support (severe outcome). Subgroup analyses of patients who were hospitalized or died were conducted. General and SSc-specific characteristics and treatment were compared over the waves. Descriptive statistics and multivariate logistic regression were applied. RESULTS: A total of 333 patients were included; 57 patients (17%) had a severe outcome, and 30 patients (9%) died. Compared to wave 1, significantly fewer patients with SSc suffered from severe COVID-19 in waves 2 and 3 (28.2% vs 9.8% and 12.7%; P < 0.001), fewer patients required hospitalization (46.7% vs 19.6% and 25.5%; P < 0.001) or ventilatory support (24.0% vs 8.7% and 10.9%; P = 0.001), and fewer patients died (15.7% vs 5.0% and 7.5%; P = 0.011). Patients were significantly younger, more often men, had less frequent arterial hypertension, and less SSc cardiac involvement over waves 1 to 3. Patients received significantly less medium to high doses of corticosteroids as they did SSc treatment. CONCLUSION: The outcome of patients with both SSc and COVID-19 improved significantly over time because of intrinsic and extrinsic factors.
引用
- Deibel E, Carreira PE, Vonk M, et al. Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time? Arthritis Care Res (Hoboken). 2023. PMID: 37667424. doi:10.1002/acr.25226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。